Todd Wood, MD
Interventional Cardiology · Lancaster, PANPI 1730305764
Payments from drug & device makers
Across 45 payments — averaging $522.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Silk Road Medical, Inc.$23K
- Heartflow, Inc.$235
- Abiomed$173
- Biosense Webster, Inc.$105
- AstraZeneca$99
- Boston Scientific$93
- plus $197 from 3 others
What the payments were for
- Consulting fees$18,87580%
- Travel & lodging$2,79012%
- Food & beverage$1,7708%
- Education$990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Silk Road Medical, Inc. | 28 | $22,633 |
| Heartflow, Inc. | 1 | $235 |
| Abiomed | 7 | $173 |
| Biosense Webster, Inc. | 1 | $105 |
| AstraZeneca | 1 | $99 |
| Boston Scientific | 1 | $93 |
| Bard Peripheral Vascular, Inc. | 1 | $71 |
| Medtronic(2 entities) | 3 | $64 |
| Inari Medical, Inc. | 2 | $62 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENROUTE Transcarotid Neuroprotection System$29,482
- ENROUTE Transcarotid Stent$21,157
- ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$7,125
- ENHANCE Transcarotid Peripheral Access Kit$1,319
- ENROUTE Transcarotid Stent System$1,200
- ENROUTE 0.014 Guidewire$1,200
- FFRct$235
- ENROUTE .014 Guidewire$119
- Carto 3$105
How this compares
$23,534 in reported general payments places this provider in the 65th percentile of 281 interventional cardiology providers in Pennsylvania.
See all interventional cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoprolol Succinate | 24 | $565 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 34 | $555 |
| ClopidogrelClopidogrel Bisulfate | 49 | $408 |
| Rosuvastatin Calcium | 20 | $239 |
| Atorvastatin Calcium | 14 | $233 |
| Amlodipine Besylate | 13 | $137 |
| Lisinopril | 14 | $86 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Lancaster
- Rolf AndersenLancaster$265K
- William GrayWynnewood$3.3M
- Eric GnallWynnewood$2.4M
- Howard HerrmannPhiladelphia$2.2M
- Ramzi KhalilPittsburgh$1.6M
- Nishant SethiScranton$1.3M
- Matthew BeckerErie$1.3M
- David LasordaPittsburgh$1.1M
- Nainesh PatelAllentown$1.1M
- Jay GiriPhiladelphia$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.